New trial aims to stop deadly bleeding after birth

NCT ID NCT06481995

Recruiting now Disease control Sponsor: Christian Haslinger Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a clotting protein called factor XIII early can reduce blood loss in women with heavy bleeding after childbirth. About 988 women having a vaginal delivery will be randomly assigned to receive either factor XIII plus standard care or standard care alone. The goal is to prevent severe complications and improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COAGULATION DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blood coagulation disease coagulation protein disease Hemorrhage Postpartum Hemorrhage puerperal disorder vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COAGULATION DISORDER COAGULATION FACTOR DEFICIENCY HEMORRHAGE POSTPARTUM COMPLICATION POSTPARTUM HEMORRHAGE

Contacts and locations

Locations

Cantonal Hospital Baden
RECRUITING

Baden, 5404, Switzerland
Cantonal Hospital St. Gallen
RECRUITING

Sankt Gallen, 9007, Switzerland
Cantonal Hospital Winterthur
RECRUITING

Winterthur, Canton of Zurich, 8401, Switzerland
Inselspital-University Hospital Bern
RECRUITING

Bern, 3010, Switzerland
Spital Zollikerberg
RECRUITING

Zollikerberg, Canton of Zurich, 8125, Switzerland
University Hospital Basel
RECRUITING

Basel, 4031, Switzerland
University Hospital Geneva
NOT_YET_RECRUITING

Geneva, Canton of Geneva, 1205, Switzerland
University Hospital Lausanne
RECRUITING

Lausanne, 1005, Switzerland
University Hospital of Zurich
RECRUITING

Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.